Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also issued reports about the stock. Needham & Company LLC raised their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research cut their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Morgan Stanley cut their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Personalis has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Stock Up 1.8%

Shares of NASDAQ:PSNL opened at $9.59 on Friday. The firm has a market capitalization of $1.00 billion, a PE ratio of -9.40 and a beta of 2.28. Personalis has a twelve month low of $3.84 and a twelve month high of $12.53. The company has a 50-day moving average price of $7.55 and a two-hundred day moving average price of $8.26.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Analysts anticipate that Personalis will post -1.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher M. Hall sold 80,091 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.02, for a total value of $882,602.82. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,387,984.33. This represents a 16.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,799 shares of company stock worth $2,031,692 over the last ninety days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Personalis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc purchased a new position in Personalis during the 2nd quarter valued at $30,000. International Assets Investment Management LLC purchased a new position in Personalis during the 4th quarter valued at $31,000. BNP Paribas Financial Markets increased its position in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares during the period. Finally, Focus Partners Wealth purchased a new position in Personalis during the 1st quarter valued at $47,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.